One of the most discussed topics in the pharmaceutical industry in recent years has been nitrosamine contamination. Nitrosamines are compounds with potentially carcinogenic properties, the detection of which in some pharmaceuticals has led to large-scale recalls worldwide. For this reason, nitrosamine analysis in pharmaceuticals must be carefully conducted in accordance with international pharmacopoeias (EP, USP, BP, JP).
What are Nitrosamines?
Nitrosamines are chemical compounds typically formed by the reaction of secondary amines with nitrites. They can unintentionally form during industrial processes, in food products, and during the manufacturing of pharmaceuticals. As most of these substances can have carcinogenic effects on human health with prolonged exposure, they are strictly controlled by international authorities.
Sources of Nitrosamines in Pharmaceuticals
Nitrosamines can occur at various stages of the pharmaceutical manufacturing process:
- Raw material impurities
- Reagents or solvents used during manufacturing
- Formation of by-products
- Migration from packaging materials
- Degradation during storage and shelf life
These risks have particularly emerged in products such as sartan-group antihypertensives, Metformin, and Ranitidine.
International Standards: EP, USP, BP, JP Approaches
To prevent nitrosamine contamination worldwide, the pharmaceutical industry is guided by four fundamental sources:
- EP (European Pharmacopoeia): Establishes nitrosamine limits and mandatory validation methods.
- USP (United States Pharmacopeia): Provides guidelines for nitrosamine analysis methods and limit tests.
- BP (British Pharmacopoeia): Includes quality control requirements in parallel with the European Pharmacopoeia.
- JP (Japanese Pharmacopoeia): Establishes quality and safety standards that mandate nitrosamine analysis.
The objective of all these standards is to establish limits that do not endanger human health and to apply reliable analytical methods.
Why is Nitrosamine Analysis Important?
- Prevention of Cancer Risks
- Conformity of approved medicinal products with international regulations
- Minimizing recall risk
- Ensuring patient safety
- Manufacturer's reputation and compliance with legal regulations
Nitrosamine analysis is not merely a mandated regulatory process, but also a crucial step in quality assurance for the protection of human health.
Effective analysis for drug safety
Pharmaceutical manufacturers and importers must conduct a nitrosamine risk assessment at every stage of their products and mitigate these risks through analyses compliant with international standards. Rigorous nitrosamine testing, in accordance with pharmacopoeias such as EP, USP, BP, and JP, ensures both product quality and public health.
Should you require nitrosamine analyses for your medicinal products or seek further information, you may contact competent and accredited laboratories.